Literature DB >> 34104326

Renal Denervation in Hypertension.

Usman S Ansari1, Benjamin J Lee2.   

Abstract

The column in this issue is supplied by Drs. Benjamin Lee, MD, and Usman Ansari, DO. Dr. Lee is an assistant professor of clinical medicine at the Houston Methodist Institute for Academic Medicine and Weill Cornell Medical College. After earning his medical degree at Harvard Medical School, Dr. Lee completed a residency in internal medicine and a nephrology fellowship at the University of California San Francisco (UCSF) while simultaneously obtaining a master of advanced study in clinical research from the UCSF departments of Epidemiology and Biostatistics. He maintains his clinical practice with the Houston Kidney Consultants. Dr. Ansari earned a Doctor of Osteopathy from Touro University College of Osteopathic Medicine in California and is completing his internal medicine residency at Houston Methodist.

Entities:  

Keywords:  hypertension; renal denervation

Mesh：

Year:  2021        PMID： 34104326      PMCID： PMC8158440          DOI： 10.14797/TPCC5120

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN： 1947-6108


  10 in total

1.  Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension.

Authors:  Mathias C Brandt; Felix Mahfoud; Sara Reda; Stephan H Schirmer; Erland Erdmann; Michael Böhm; Uta C Hoppe
Journal:  J Am Coll Cardiol       Date:  2012-03-06       Impact factor: 24.094

2.  Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension.

Authors:  Felix Mahfoud; Bodo Cremers; Julia Janker; Britta Link; Oliver Vonend; Christian Ukena; Dominik Linz; Roland Schmieder; Lars Christian Rump; Ingrid Kindermann; Paul Andrew Sobotka; Henry Krum; Bruno Scheller; Markus Schlaich; Ulrich Laufs; Michael Böhm
Journal:  Hypertension       Date:  2012-06-25       Impact factor: 10.190

3.  Renal denervation in moderate to severe CKD.

Authors:  Dagmara Hering; Felix Mahfoud; Antony S Walton; Henry Krum; Gavin W Lambert; Elisabeth A Lambert; Paul A Sobotka; Michael Böhm; Bodo Cremers; Murray D Esler; Markus P Schlaich
Journal:  J Am Soc Nephrol       Date:  2012-05-17       Impact factor: 10.121

4.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

Authors:  Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm
Journal:  Lancet       Date:  2010-11-17       Impact factor: 79.321

5.  Predictive Role of Nighttime Blood Pressure in Response to Renal Denervation: Evidence From the DENER-HTN Study (Renal Denervation for Hypertension).

Authors:  Dagmara Hering
Journal:  Hypertension       Date:  2017-01-23       Impact factor: 10.190

6.  Renal Denervation.

Authors:  Reetu R Singh; Kate M Denton
Journal:  Hypertension       Date:  2018-09       Impact factor: 10.190

7.  A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN).

Authors:  Karl Fengler; Karl-Philipp Rommel; Stephan Blazek; Christian Besler; Philipp Hartung; Maximilian von Roeder; Martin Petzold; Sindy Winkler; Robert Höllriegel; Steffen Desch; Holger Thiele; Philipp Lurz
Journal:  Circulation       Date:  2019-01-29       Impact factor: 29.690

8.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.

Authors:  Michel Azizi; Roland E Schmieder; Felix Mahfoud; Michael A Weber; Joost Daemen; Justin Davies; Jan Basile; Ajay J Kirtane; Yale Wang; Melvin D Lobo; Manish Saxena; Lida Feyz; Florian Rader; Philipp Lurz; Jeremy Sayer; Marc Sapoval; Terry Levy; Kintur Sanghvi; Josephine Abraham; Andrew S P Sharp; Naomi D L Fisher; Michael J Bloch; Helen Reeve-Stoffer; Leslie Coleman; Christopher Mullin; Laura Mauri
Journal:  Lancet       Date:  2018-05-23       Impact factor: 79.321

9.  Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial.

Authors:  Jonathan S Steinberg; Vitaliy Shabanov; Dmitry Ponomarev; Denis Losik; Eduard Ivanickiy; Evgeny Kropotkin; Konstantin Polyakov; Pawel Ptaszynski; Boris Keweloh; Christopher J Yao; Evgeny A Pokushalov; Alexander B Romanov
Journal:  JAMA       Date:  2020-01-21       Impact factor: 56.272

10.  Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.

Authors:  Michael Böhm; Kazuomi Kario; David E Kandzari; Felix Mahfoud; Michael A Weber; Roland E Schmieder; Konstantinos Tsioufis; Stuart Pocock; Dimitris Konstantinidis; James W Choi; Cara East; David P Lee; Adrian Ma; Sebastian Ewen; Debbie L Cohen; Robert Wilensky; Chandan M Devireddy; Janice Lea; Axel Schmid; Joachim Weil; Tolga Agdirlioglu; Denise Reedus; Brian K Jefferson; David Reyes; Richard D'Souza; Andrew S P Sharp; Faisal Sharif; Martin Fahy; Vanessa DeBruin; Sidney A Cohen; Sandeep Brar; Raymond R Townsend
Journal:  Lancet       Date:  2020-03-29       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.